Last reviewed · How we verify

Methazolamide Pill

University of Waterloo · FDA-approved active Small molecule

Methazolamide inhibits carbonic anhydrase, reducing aqueous humor production in the eye to lower intraocular pressure.

Methazolamide inhibits carbonic anhydrase, reducing aqueous humor production in the eye to lower intraocular pressure. Used for Glaucoma, Ocular hypertension, Angle-closure glaucoma (acute attacks).

At a glance

Generic nameMethazolamide Pill
SponsorUniversity of Waterloo
Drug classCarbonic anhydrase inhibitor
TargetCarbonic anhydrase
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Methazolamide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor by inhibiting the enzyme carbonic anhydrase in the ciliary body of the eye. By reducing aqueous humor formation, the drug lowers intraocular pressure, which helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension. It is a systemic (oral) medication with a longer duration of action compared to topical carbonic anhydrase inhibitors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: